09.09.10
Patheon 3Q
3Q Revenues: $163.3 million (-1%)
3Q Loss: $3.0 million (loss of $5.2 million in 3Q09)
YTD Revenues: $493.5 million (+3%)
YTD Loss: $2.4 million (loss of $4.9 million YTD09)
Comments: Revenues from commercial manufacturing operations were down 2% to $130.2 million. North American commercial revenues increased $5.3 million, or 9% due to improved production in PR and favorable foreign exchange. European commercial revenues were down $8.0 million or 11% due to reduced volumes in Bourgoin. Pharmaceutical Development Services were up 5% to $33.1 million. Loss in the quarter includes $6.1 million of costs associated with the closure of the Caguas facility.
3Q Revenues: $163.3 million (-1%)
3Q Loss: $3.0 million (loss of $5.2 million in 3Q09)
YTD Revenues: $493.5 million (+3%)
YTD Loss: $2.4 million (loss of $4.9 million YTD09)
Comments: Revenues from commercial manufacturing operations were down 2% to $130.2 million. North American commercial revenues increased $5.3 million, or 9% due to improved production in PR and favorable foreign exchange. European commercial revenues were down $8.0 million or 11% due to reduced volumes in Bourgoin. Pharmaceutical Development Services were up 5% to $33.1 million. Loss in the quarter includes $6.1 million of costs associated with the closure of the Caguas facility.
